With the aim to further improve personalized treatment strategies in AML based on distinct OXPHOS signatures, we evaluated the efficacy of ETC I (rotenone) and several ETC II inhibitors (thenoyltrifluoroacetone (TTFA) and 3-Nitropropionic acid (3-NPA)) in FLT3-ITD+ versus FLT3-wt AMLs and healthy CB-derived CD34+ cells. This evidence concerns the gene FLT3 and acute myeloid leukemia.